Add a new dimension of insights to your view of cancer with Guardant Infinity.
Genomics alone provides a narrow view of cancer. Epigenomic insights are critical to understanding cancer biology that genomics alone cannot elucidate.1,2
The epigenome can help explain diverse phenotypes that do not harbor genetic variation3
Within the last decade, up to 42% of FDA-approved therapies were biomarker driven.4
However, among all patients with cancer, >80% are still ineligible for genomic precision medicine approaches.5
Home Guardant Infinity™ for BioPharma Guardant360® CDx for BioPharma InfinityAI for BioPharma
Guardant Infinity is for Research Use Only. Not for use in diagnostic procedures
InfinityAI is not a standalone customer product. “Powered by InfinityAI” refers to Guardant Health artificial intelligence and machine learning technology used in development of product features. These features are reported as professional service and have not been cleared or approved by the US FDA.